17.01.2013 - In the controversy over the harmlessness of GM maize, the EU food watchdog EFSA has published all data from its safety assessment of Monsanto’s NK603.
The EFSA’s move was triggered by „the level of public interest“ after Caen-based researcher Gilles-Eric Séralini claimed Monsanto’s GM maize NK603 harmed the health of lab rats in an experimental setting last September. However, researchers all over the world challenged Seralini’s findings saying his data were insufficient and would require publication of the raw data.
Up to now, the scientific head of the GMO-sceptic organisation Criigen refused to do so. But in a press conference at the European Parliament Séralini announced he will publish his data now as the EFSA opened up its data first. The EFSA, which reviews the use and authorisation of GM crops and foodstuffs, in November rejected a report by Seralini which linked NK603 to cancer found in laboratory rats as failing to meet “acceptable scientific standards.“ The EFSA decision is part of a major initiative designed to facilitate access to data, enhancing transparency in risk assessment. “Risk assessment is an evolving science and EFSA is always willing to review its past work should new robust science bring a new perspective to any of the Authority’s previous findings, „ said EFSA chief Catherine Geslain-Lanéelle.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.